Skip to main content

FutureCorp Space Acquisition 1

Filed May 20, 2026.

View on SEC.gov

About this filing

A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.

period unavailable · Filed May 20, 2026

FTRA$9.870.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Dilution

The difference between the public offering price per unit and the NTBV per Class A ordinary share after this offering constitutes the dilution to investors in this offering. NTBV per share is determined by dividing our NTBV, which is our total tangible assets less total liabilities (including the value of Class A ordinary shares that may be redeemed for cash), by the number of outstanding Class A ordinary shares.

The below calculations (A) assume that (i) no ordinary shares are issued to shareholders of a potential business combination target as consideration or issuable by a post-business combination company, for instance under an equity or employee share purchase plan, (ii) no ordinary shares and convertible equity or debt securities are issued in connection with additional financing that we may seek in connection with an initial business combination, (iii) no working capital loans are converted into private placement warrants, as further described in this prospectus and (iv) no value is attributed to the warrants (however, we may need to issue ordinary shares or convertible equity or debt securities in the circumstances described above, as we intend to target an initial business combination with a target company whose enterprise value is greater than the net proceeds of the offering and the sale of private placement warrants) and (B) assume the issuance of 20,000,000 Class A ordinary shares (or 23,000,000 Class A ordinary shares if the over-allotment option is exercised in full) and 5,750,000 founder shares (up to 750,000 of which are assumed to be forfeited in the scenario in which the over-allotment option is not exercised in full). Such calculations do not reflect any dilution associated with the exercise of warrants as the warrants are accounted for as equity and are only exercisable following the consummation of our initial business combination. The assumed exercise of the warrants would cause the actual dilution to the public shareholders to be higher, particularly where a cashless exercise is utilized. Further, we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of this offering and the sale of the private placement warrants, and, as a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemptions by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. The issuance of additional ordinary or preference shares may significantly dilute the equity interest of public shareholders, which dilution would even further increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares.

The following table illustrates the difference between the public offering price per unit and our NTBV per share, as adjusted to give effect to this offering and assuming redemption of our public shares at varying levels and the full exercise and no exercise of the over-allotment option:

As of March 31, 2026
Offering Price of $10.00 per Unit · 25% of Maximum Redemption · 50% of Maximum Redemption · 75% of Maximum Redemption · Maximum Redemption
NTBVNTBVDifference between NTBV and Offering PriceNTBVDifference between NTBV and Offering PriceNTBVDifference between NTBV and Offering PriceNTBVDifference between NTBV and Offering Price
Assuming Full Exercise of Over-Allotment Option
$7.70$7.13$2.87$6.17$3.83$4.26$5.74$(1.49)$11.49
Assuming No Exercise of Over-Allotment Option
$7.72$7.15$2.85$6.21$3.79$4.31$5.69$(1.38)$11.38

For each of the redemption scenarios above, the NTBV was calculated as follows:

No Redemptions25% of Maximum Redemptions50% of Maximum Redemptions75% of Maximum RedemptionsMaximum Redemptions
With Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- Allotment
Public offering price$10.00$10.00$10.00$10.00$10.00$10.00$10.00$10.00$10.00$10.00
Net tangible book deficit before this offering(0.01)(0.01)(0.01)(0.01)(0.01)(0.01)(0.01)(0.01)(0.01)(0.01)
Increase attributable to public shareholders7.737.717.167.146.226.184.324.27(1.37)(1.48)
Pro forma net tangible book value after this offering and the sale of the private placement shares7.727.707.157.136.216.174.314.26(1.38)(1.49)
Dilution to public shareholders$2.28$2.30$2.85$2.87$3.79$3.83$5.69$5.74$11.38$11.49
Percentage of dilution to public shareholders22.80%23.00%28.50%28.70%37.90%38.30%56.90%57.40%113.80%114.90%
No Redemptions25% of Maximum Redemptions50% of Maximum Redemptions75% of Maximum RedemptionsMaximum Redemptions
With Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- AllotmentWith Over- AllotmentWithout Over- Allotment
Numerator:
Net tangible book deficit before this offering$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)$(55,810)
Net proceeds from this offering and the sale of the private placement shares(1)201,250,000231,250,000201,250,000231,250,000201,250,000231,250,000201,250,000231,250,000201,250,000231,250,000
Plus: Offering costs accrued for or paid in advance, excluded from tangible book value62,04962,04962,04962,04962,04962,04962,04962,04962,04962,049
Less: Deferred underwriting commissions(2)(8,000,000)(9,800,000)(8,000,000)(9,800,000)(8,000,000)(9,800,000)(8,000,000)(9,800,000)(8,000,000)(9,800,000)
Less: Overallotment liability(158,500)—(158,500)—(158,500)—(158,500)—(158,500)—
Less: Amounts paid for redemptions(3)——(50,000,000)(57,500,000)(100,000,000)(115,000,000)(150,000,000)(172,500,000)(200,000,000)(230,000,000)
$193,097,739$221,456,239$143,097,739$163,956,239$93,097,739$106,456,239$43,097,739$48,956,239$(6,902,261)$(8,543,761)
Denominator:
Ordinary shares outstanding prior to this offering5,750,0005,750,0005,750,0005,750,0005,750,0005,750,0005,750,0005,750,0005,750,0005,750,000
Ordinary shares forfeited if over-allotment is not exercised(750,000)—(750,000)—(750,000)—(750,000)—(750,000)—
Ordinary shares offered and sale of private placement shares20,000,00023,000,00020,000,00023,000,00020,000,00023,000,00020,000,00023,000,00020,000,00023,000,000
Less: Ordinary shares redeemed——(5,000,000)(5,750,000)(10,000,000)(11,500,000)(15,000,000)(17,250,000)(20,000,000)(23,000,000)
25,000,00028,750,00020,000,00023,000,00015,000,00017,250,00010,000,00011,500,0005,000,0005,750,000

(1) Expenses applied against gross proceeds include offering expenses of approximately $750,000 and underwriting commissions of $0.20 per unit (other than those units sold pursuant to the underwriters’ option to purchase additional units), or $4,000,000 in the aggregate (whether or not the underwriters’ option to purchase additional units is exercised), payable to Cantor Fitzgerald & Co. (excluding deferred underwriting commissions). See “Use of Proceeds.”

(2) Upon the consummation of our initial business combination, the deferred underwriting commissions would be paid as follows: $0.40 per unit on units other than those sold pursuant to the underwriters’ option to purchase additional units and $0.60 per unit on units sold pursuant to the underwriters’ option to purchase additional units, or $8,000,000 in the aggregate or up to $9,800,000 in the aggregate if the underwriters’ over-allotment option is exercised in full payable to Cantor Fitzgerald & Co, for deferred underwriting commissions. See also “Underwriting” for a description of compensation and other items of value payable to the underwriters.

(3) If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders, directors, officers or their respective affiliates may purchase shares or public warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See“Proposed Business — Effecting Our Initial Business Combination — Permitted Purchases of Our Securities.”

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.